Safeguard Scientifics Q2 net loss narrows to $0.3M; expects $43M from Flashtalking sale

SAFEGUARD SCIENTIFICS INC

2021-Q2 EPS reported $0.83

Net loss of $0.3M ($0.02 per share) vs loss of $9.9M ($0.48) in Q2 2020; improvement driven by $9.2M in gains.
Receives $3.4M cash from Velano Vascular sale, recording a $1.8M gain; no new deployments in Q2.
Bright Health IPO converted preferred equity to 1,322,484 shares valued at $22.7M (June 30); value fell to ~$11M by Aug 10.
Flashtalking signs definitive agreement to be acquired by Mediaocean; Safeguard expects ~$43M cash in Q3 2021.
Carrying value of ownership interests $60.1M (cost $173.5M); recorded $2.5M impairment on other interests.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.